Press Room

2023 CPhI Worldwide

Start
Tuesday, October 24, 2023 - 00:00
End
Thursday, October 26, 2023 - 00:00
Location: Barcelona, Spain
Booth Number: 3L20
2023_CPhI Barcelona_Hovione

Join Hovione at CPhI Worldwide and meet the team in whose attentive hands you can place your project.

Let’s discuss your project together.

Schedule a meeting button | Hovione

 

 

We look forward to seeing you at CPhI Worldwide

to present the most reliable and innovative end-to-end solutions to help your project succeed.

 

Also interested:

The Future is Continuous

Meet our experts and find out if

Continuous Tableting is right for your product​​​​​

 

The Leader in Spray Drying

Contact our experts to overcome your

solubility issues with the best scale-up science

 

Dispersome® 

Learn more about the innovative technology

capable of solving the poor solubility issues of your drug candidate

 

ASD-Hipros 

Meet our experts to identify the best performing

and stable formulations for your drug

 

Everything for Inhalation

Meet our experts to bring your

Inhaled medicine to patients

 

The Specialist Integrated CDMO

Contact our experts to take your project

to market faster​​​

 

Schedule a meeting with our experts.

 

Find more about CPhI Worldwide.

 

Also in the Press Room

See All

Integrated approach simplifies development, reduces risk, and supports scalable manufacturing. Hovione and Industrial Design Consultancy Ltd.’s (IDC) lead single-use nasal dry powder device is now available for commercial partnerships. Hovione and IDC have completed the device design and established initial device manufacturing and supply capability, enabling pharmaceutical partners to leverage existing capsule filling infrastructure. This approach simplifies development, reduces cost and risk, and helps shorten timelines to the clinic and commercialization. “This milestone marks an important step in the evolution of our collaboration with IDC — from device innovation to a fully integrated intranasal drug delivery platform,” said Márcio Temtem, Ph.D., Vice President, Strategic Business Management, Hovione. “As the industry looks for faster, more reliable ways to bring complex therapies to patients, integration becomes critical. By bringing together nasal particle engineering science, formulation manufacturing and filling, and device technologies into a single offering, we enable a more seamless and predictable development journey, accelerating the path to market for intranasal therapies.” The nasal delivery device enables broad and targeted nasal deposition flexibility while delivering maximum usability and reliability. With a patented design and manufacturing process established, the platform is available for partnering with pharmaceutical companies on an exclusive basis as part of Hovione’s integrated offering for inhalation and nasal drug development and manufacturing. Additionally, IDC’s Managing Director, Stephen Knowles Ph.D., said the companies are now “well-advanced” with the development of a multi-use device to support an even wider range of therapies and patient needs. Read the full article at ContractPharma.com    

Press Clipping

Hovione, IDC Launch Intranasal Drug Delivery Platform

May 07, 2026